Abstract Number: 0691 • ACR Convergence 2020
Denosumab Did Not Improve Computerized Tomography Erosion Scores When Added to Intensive Urate-Lowering Therapy in Gout: Results from a Pilot Study
Background/Purpose: Bone erosion is a common complication of tophaceous gout. Disordered osteoclast activity has been implicated in the pathogenesis of gouty bone erosion. We sought…Abstract Number: 0950 • ACR Convergence 2020
The Association Between Gout and Cardiovascular Disease Outcomes: Assessment and Recalibration of Individual-level Primary Prevention Risk Prediction Equations in Approximately 450,000 New Zealanders
Background/Purpose: Some studies have reported that gout is an independent risk factor for cardiovascular disease (CVD). Individual-level cardiovascular risk prediction equations have been developed and…Abstract Number: 0952 • ACR Convergence 2020
Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial
Background/Purpose: Pegloticase, a recombinant, pegylated uricase, is used for treatment of gout in patients who fail oral urate lowering therapy (ULT). Despite successful reduction of…Abstract Number: 0953 • ACR Convergence 2020
Long-term Xanthine Oxidase Inhibitor Treat to Target Urate Lowering Therapy Coordinately Re-wires the Mononuclear Leukocyte Mitochondrial and Inflammatory Proteome in Gout
Background/Purpose: In gout, long-term xanthine oxidase inhibitor treat to target urate lowering therapy (XOIT2T) markedly reduces flares and synovitis, despite delayed resolution of tissue crystal…Abstract Number: 0954 • ACR Convergence 2020
Dual-energy CT Predicts Mortality in Gout Patients: A 3-year Follow-up Cohort Study
Background/Purpose: Cardiovascular events, chronic kidney disease and increased mortality are common in gout patients but what links them remains unclear. Tophaceous gout in particular is…Abstract Number: 1016 • ACR Convergence 2020
Annual Cardiac or Orthopedic Procedure Volume in Gout versus Rheumatoid Arthritis: A National Time-trends Study
Background/Purpose: The hospitalization rate for gout has been increasing in recent years with a reduction in people with RA. To our knowledge, there are no…Abstract Number: 1466 • ACR Convergence 2020
Multimorbidity in Rheumatoid Arthritis, Psoriatic Arthritis, Gout, and Osteoarthritis Within the Rheumatology Informatics System for Effectiveness (RISE) Registry
Background/Purpose: Rheumatic and musculoskeletal diseases (RMDs) often predispose the development of other chronic conditions, resulting in multimorbidity. While multimorbidity is increasingly being recognized and examined…Abstract Number: 1542 • ACR Convergence 2020
The Role of Dual Energy Computed Tomography (DECT) in the Differentiation of Gout and Calcium Pyrophosphate Deposition Disease
Background/Purpose: Differentiation of gout and calcium pyrophosphate deposition disease (CPPD) is sometimes difficult as patients often present with a similar clinical picture. Arthrocentesis and subsequent…Abstract Number: 1573 • ACR Convergence 2020
Gout as an Immune-Related Adverse Event from Immune Checkpoint Inhibitors
Background/Purpose: Immune checkpoint inhibitors (ICI) are novel treatments approved for various tumours including melanoma, lung and kidney. By interacting with immunoregulatory molecules (programmed death-1 (PD-1),…Abstract Number: 1607 • ACR Convergence 2020
Effectiveness of Dietary Counseling on Gout Management and Risk Factors for Metabolic Syndrome in Gout Patients
Background/Purpose: Gout is the most prevalent inflammatory arthritis globally. Despite treatment advances, the prevalence of gout has continued to increase over the last several decades.…Abstract Number: 1628 • ACR Convergence 2020
Management of Gout After Pegloticase; Observations of US Clinical Practice from Trio Health and the American Rheumatology Network (ARN)
Background/Purpose: Pegloticase is approved for severe gout in patients that are intolerant to, or whose disease is ineffectively controlled by, other uric acid lowering therapies…Abstract Number: 1629 • ACR Convergence 2020
Management of Gout with Pegloticase; Real-World Utilization and Outcomes from Trio Health and the American Rheumatology Network (ARN)
Background/Purpose: Infusion reactions and other adverse events associated with pegloticase may lead to discontinuation of treatment in patient populations that have already failed or are…Abstract Number: 25 • 2019 ACR/ARP Annual Meeting
Altered Distribution and Enhanced Osteoclastogenesis of Mucosal-associated Invariant T Cells in Gouty Arthritis
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are subsets of innate invariant T cells and rapidly produce Th1/Th17 cytokines including interferon (IFN)-γ, tumor necrosis factor (TNF)-α,…Abstract Number: 154 • 2019 ACR/ARP Annual Meeting
Enhancing Medicine Trainees’ Exposure to Gout Diagnosis and Management Through an Interprofessional Approach in the Primary Care Setting
Background/Purpose: Gout is common in primary care, though patients often have inadequate control or are referred to specialists for evaluation and management. This may be…Abstract Number: 257 • 2019 ACR/ARP Annual Meeting
Alcohol Use Hospitalizations in People with Gout, Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia, and Low Back Pain Are Increasing: A Time-trends Study Using the U.S. National Data
Background/Purpose: Alcohol abuse and associated mortality is an important public health problem in the U.S. To our knowledge, limited data are available on alcohol use…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »